U.S. regulators recently asked Sarepta Therapeutics to voluntarily halt shipments of its Elevidys gene therapy after a ...

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...

Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Sarepta Therapeutics (NASDAQ:SRPT) surges 40% post-market after strategic restructuring, workforce cuts, pipeline focus, and ...

The gene-therapy company is restructuring, laying off 36% of its workforce and making changes to its executive team.

Shares of struggling drug developer Sarepta Therapeutics skyrocketed nearly 40% in extended trading Wednesday after the ...

Fintel reports that on July 21, 2025, Needham downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Hold to ...

Fintel reports that on July 21, 2025, Leerink Swann downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...